NCT02200172View on ClinicalTrials.gov

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Cancer
Interventions
OTHER

Melatonin

Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).

OTHER

Placebo

Trial Locations (1)

K1N 5C8

Bruyère Continuing Care, Ottawa

Sponsors
All Listed Sponsors
lead

Bruyère Health Research Institute.

OTHER